EHA 2023 | The benefit of CPX-351 over 7+3 in patients with sAML by baseline bone marrow percentage

This is a sub-analysis of this pivotal trial where CPX was compared to standard chemotherapy in patients with secondary AML. And the rationale for this analysis is because we know that the blast percentage could be a risk factor – so higher blast may be associated with an increased risk for these patients – but also because some patients were included with less than 20% blast, which is a unique category that makes it into AML because of their molecular abnormalities that are associated with AML, but they don’t quite have the 20% blast. So we wanted to see if the benefit of CPX that we saw in the overall analysis of this study extended to all of the categories or to some categories in particular. And what we found in this analysis is that indeed the benefit of CPX over 3+7 extends to all of these subsets of patients, whether it’s less than 20% or it’s 20 to 40, 40 to 60 or greater than 60%. So that’s important just so that we know that any patient that has, of course, secondary AML, which is where CP is approved, could benefit regardless of the blast percentage at the time of diagnosis.